A non-clinical comparative study of IL-23 antibodies in psoriasis

• প্রধান লেখক: Li Zhou (লেখক), Yibing Wang (লেখক), Qi Wan (লেখক), Fei Wu (লেখক), Jeffrey Barbon (লেখক), Robert Dunstan (লেখক), Stephen Gauld (লেখক), Mark Konrad (লেখক), Laura Leys (লেখক), Richard McCarthy (লেখক), Marian Namovic (লেখক), Christine Nelson (লেখক), Gary Overmeyer (লেখক), Denise Perron (লেখক), Zhi Su (লেখক), Leyu Wang (লেখক), Susan Westmoreland (লেখক), Jun Zhang (লেখক), Rui Zhu (লেখক), Geertruida Veldman (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode...